



Truxima[®] (rituximab-abbs) – First-time biosimilar launch

- On November 7, 2019, [Teva and Celltrion announced](#) the launch of [Truxima \(rituximab-abbs\)](#), a biosimilar to Genentech's [Rituxan[®] \(rituximab\)](#).
 - Truxima will be available during the week of November 11, 2019.
 - Pfizer has also received approval for its biosimilar Rituxan, [Ruxience[™] \(rituximab-pvvr\)](#). It is projected to launch in January 2020.
- Truxima and Rituxan share all of the same oncology indications for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
- In addition, Rituxan is approved for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's Granulomatosis) and microscopic polyangiitis, and pemphigus vulgaris.
- Similar to Rituxan, Truxima carries a boxed warning for fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
- The wholesale acquisition cost (WAC) of Truxima is \$845.55 for the 100 mg vial and \$4227.75 for the 500 mg vial. This is 10% lower than the WAC for Rituxan.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.